SONOMA PHARMACEUTICALS INC (SNOA)
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
$1.33+0.76%
Close 2026-09-04 · 1-day change
NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-09-04
QuarterlyIQ Insights · SNOA
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2012 | Mar 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 21.9 | 19.5 | 14.3 | 12.7 | 13.3 | 12.6 | 18.6 | 17.9 | 19.0 | 16.7 | 12.8 | 9.4 | 13.9 | 13.7 | 15.5 | 12.7 |
| Total Revenues | 21.9 | 19.5 | 14.3 | 12.7 | 13.3 | 12.6 | 18.6 | — | 19.0 | 16.7 | 12.8 | 9.4 | 13.9 | 13.7 | 15.5 | 12.7 |
| Cost of Revenues | — | 12.1 | 8.8 | 8.0 | 8.8 | 8.6 | 12.1 | 9.8 | 10.1 | 9.3 | 7.2 | 6.7 | 6.6 | 5.3 | 4.7 | 4.0 |
| Gross Profit | 8.5 | 7.4 | 5.5 | 4.7 | 4.5 | 4.0 | 6.6 | 8.1 | 8.9 | 7.3 | 5.7 | 2.6 | 7.3 | 8.4 | 10.7 | 8.7 |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 7.7 | 7.6 | 7.4 | 7.6 | 8.8 | 9.8 | 9.5 | 14.2 | 18.6 | 19.9 | 17.1 | 15.6 | 12.4 | 11.6 | 11.9 | 13.2 |
| R&D Expenses | 2.3 | 2.3 | 1.8 | 1.9 | 0.2 | 0.1 | 0.6 | 1.3 | 1.5 | 1.6 | 1.6 | 1.8 | 1.5 | 2.9 | 2.2 | 2.0 |
| Other Operating Expenses, Total | (1.1) | (1.0) | 0.8 | (0.3) | (0.6) | (0.4) | (0.6) | 0.2 | (0.2) | (0.3) | 0.0 | — | — | — | — | — |
| Operating Income | (1.4) | (2.5) | (3.7) | (4.7) | (4.6) | (5.9) | (3.4) | (7.4) | (11.3) | (14.2) | (13.0) | (14.7) | (6.7) | (6.1) | (3.4) | (6.5) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | — | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 1.1 | 1.1 | 0.9 |
| Interest & Investment Income | — | — | — | — | — | — | 0.0 | 0.1 | 0.2 | 0.3 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Net Interest Expenses | — | — | — | — | — | — | (0.0) | (0.0) | (0.2) | (0.2) | (0.0) | 0.0 | 0.0 | 1.1 | 1.1 | 0.9 |
| Asset Writedown | — | — | — | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — | — | — | — |
| EBT, Incl. Unusual Items | (2.5) | (3.4) | (2.9) | (5.0) | (5.2) | (5.4) | (3.9) | (3.5) | (11.3) | (14.3) | (12.9) | — | — | — | — | — |
| Income Tax Expense | — | (0.2) | 0.6 | (0.2) | (0.0) | (0.3) | 0.7 | 0.0 | 0.5 | 0.1 | (4.3) | 0.0 | 0.0 | 0.0 | 0.0 | — |
| Earnings from Continuing Operations | — | — | — | — | — | (5.1) | (4.6) | (3.6) | — | (14.3) | (8.7) | — | — | — | — | — |
| Net Income | ||||||||||||||||
| Net Income | 0.9 | (3.2) | (3.5) | (4.8) | (5.2) | (5.1) | (4.0) | (3.3) | (11.8) | (14.3) | 9.3 | (10.2) | (8.2) | 3.7 | (5.4) | (7.3) |
| Per Share | ||||||||||||||||
| Basic EPS | 0.24 | (1.89) | (2.79) | (0.53) | (1.52) | (1.92) | — | — | — | — | — | — | (0.85) | 0.54 | — | — |
| Diluted EPS | 0.24 | (1.89) | (2.79) | (0.53) | (1.52) | (1.92) | — | — | — | — | — | — | (0.85) | 0.54 | — | — |
| Revenue per Share | 5.70 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 3.8 | 1.7 | 1.2 | 9.1 | 3.4 | 0.0 | — | — | — | — | — | — | 9.7 | 6.9 | — | — |
| Diluted Weighted Avg Shares | 3.8 | 1.7 | 1.2 | 9.1 | 3.4 | 0.0 | — | — | — | — | — | — | 9.7 | 6.9 | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | (2.3) | (3.6) | (4.5) | (4.4) | (5.7) | (3.2) | (7.1) | (10.8) | (13.7) | (12.7) | (14.5) | (6.4) | (5.8) | (3.1) | (6.1) |
| EBIT | (1.4) | (2.5) | (3.7) | (4.7) | (4.6) | (5.9) | (3.4) | (7.4) | (11.3) | (14.2) | (13.0) | (14.7) | (6.7) | (6.1) | (3.4) | (6.5) |
| Effective Tax Rate | — | — | — | — | 0.6% | 6.1% | -18.3% | -0.8% | -4.0% | -0.4% | 33.0% | — | — | — | — | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.